CDE Granted LM-302 Breakthrough Therapy Designation for Claudin 18.2 positive GC/GEJ

2023-11-23
Share:

November 3^rd, 2023 - LaNova Medicines Ltd. announced that CDE has granted LM-302 (anti-CLDN18.2 ADC) Breakthrough Therapy Designation in October 2023. This designation is for the treatment of third-line and above Claudin 18.2-positive, locally advanced or metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma patients.

Previous

FDA Granted LM-108 Orphan Drug Designations for Cancer Treatments
Next

LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate